Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder
Yıl: 2021 Cilt: 24 Sayı: 2 Sayfa Aralığı: 153 - 159 Metin Dili: İngilizce DOI: 10.5505/kpd.2020.49404 İndeks Tarihi: 06-12-2021
Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder
Öz: Objective: Ischemia modified albumin (IMA) is analtered type of albumin produced due to exposure tohypoxia, acidosis, inflammation, or oxidative stress. Inthis study, we aimed to evaluate the serum IMA levels innewly diagnosed and medication-naive generalized an xiety disorder (GAD) and panic disorder (PD) patients.Method: This cross-sectional study included medication naive 23 GAD, 25 PD patients, and 28 healthy controls.The participants were evaluated with a sociodemograp hic form, the Beck Depression Inventory (BDI), and theBeck Anxiety Inventory (BAI). Venous blood sampleswere collected from all participants, and IMA levels androutine biochemical parameters were measured.Results: There was no statistically significant differencebetween three groups in terms of age, gender, bodymass index (BMI) and routine biochemical markers of theparticipants (p>0.05). The GAD and PD groups had sig nificantly higher serum IMA levels than healthy controls(p<0.01), whereas there was no statistically significantdifference in IMA levels between GAD and PD groups(p=0.994). Additionally, correlation analysis showed apositive correlation between IMA levels with BDI and BAIscores (r=0.449 and r=0.632, respectively,p<0.001).Discussion: Higher IMA levels in patients withGAD and PD may indicate metabolic stress on thesepatients. Anxiety disorders may tend to various bioche mical disturbances, and IMA could be an important newmarker that indicates global metabolic risk in suchpatients. This research is the first study that evaluatesIMA levels in anxiety disorders.
Anahtar Kelime: İskemi modifiye albumin: Yaygın anksiyete bozukluğu ve panik bozuklukta ki genel metabolik risk için potansiyel bir belirteç
Öz: Amaç: İskemi modifiye albümin (İMA), hipoksi, asidoz,inflamasyon, oksidatif stres sonucu üretilen modifiye biralbümin türüdür. Bu çalışmada, yeni tanı alan ve dahaönce ilaç kullanmamış yaygın anksiyete bozukluğu (YAB)ve panik bozukluk (PB) hastalarında serum İMA düzey lerinin değerlendirilmesi amaçlanmıştır. Yöntem: Bukesitsel çalışmaya, daha önce ilaç kullanmamış 23 YAB,25 PB hastası ve 28 sağlıklı kontrol dahil edildi.Katılımcılar sosyodemografik veri formu, Beck DepresyonÖlçeği (BDÖ) ve Beck Anksiyete Ölçeği (BAÖ) iledeğerlendirildi. Tüm katılımcıların serum İMA düzeylerive rutin biyokimyasal parametreleri ölçüldü. Bulgular:Katılımcıların yaş, cinsiyet, vücut kitle indeksi (VKİ) vebiyokimyasal belirteçleri açısından gruplar arasındaistatistiksel olarak anlamlı fark yoktu (p> 0.05). SerumİMA düzeyleri YAB ve PB gruplarında sağlıklı kontrolleregöre anlamlı olarak daha yüksekken (p <0,01), YAB ve PBgrupları arasında İMA düzeyleri açısından istatistikselolarak anlamlı fark yoktu (p = 0,994). Korelasyon analiz lerinde, İMA düzeyleri ile BDÖ ve BAE puanları arasındapozitif korelasyon saptandı (sırasıyla r = 0.449 ve r =0.632, p <0.001). Sonuç: YAB ve PB hastalarındaki yük sek İMA seviyeleri, bu hastalardaki metabolik stresigösterebilir. Anksiyete bozukluklarında çeşitlibiyokimyasal bozukluklar görülebilmektedir. İMA, buhastalarda genel metabolik riski gösteren önemli bir yenibelirteç olabilir. Bu araştırma, anksiyete bozukluklarındaİMA düzeylerini değerlendiren ilk çalışmadır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655-79.
- 2. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006;368 :2156–66.
- 3. Freire R, Zugliani M, Garcia R, Nardi A. Treatment–resistant panic disorder: a systematic review. Expert Opin Pharmacother 2016;17:159–68.
- 4. Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev 2009;2:63–7.
- 5. Vogelzangs N, Beekman A, De Jonge P, Penninx B. Anxiety disorders and inflammation in a large adult cohort. Transl Psychiatry 2013;3:249.
- 6. Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, Gargiulo G, Testa G, Cacciatore F, Bonaduce D, Abete P. Oxidative stress, aging, and diseases. Clin Interv Aging 2018;13:757.
- 7. Reyazuddin M, Azmi S, Islam N, Rizvi A. Oxidative stress and level of antioxidant enzymes in drug-naive schizophrenics. Indian J Psychiatry 2014;56:344.
- 8. Smaga I, Niedzielska E, Gawlik M, Moniczewski A, Krzek J, Pera J, Filip M. Pharmacological Reports Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders . Part 2 . Depression , anxiety , schizophrenia and autism. Pharmacol reports 2015;67:569–80.
- 9. Savas H, Gergerlioglu H, Armutcu F, Herken H, Yilmaz H, Kocoglu E. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 2006;7:51–5.
- 10. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011;49:177–84.
- 11. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. Eur J Biochem. 2001;268:42–7.
- 12. Roy D, Quiles J, Gaze D, Collinson P, Kaski J, Baxter G. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006;92:113–4.
- 13. Bar-Or D, Lau E, Winkler J. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311–5.
- 14. Turan T, Akyüz A, Sahin S, Kul S, Yilmaz A, Kara F, Mentese SO, Aykan AÇ, Demir SE, Celik S, Karahan SC. Association between the plasma levels of IMA and coronary atherosclerotic plaque burden and ischemic burden in early phase of non-ST-segment-elevation acute coronary syndromes. Eur Rev Med Pharmacol Sci 2017;21:576–83.
- 15. Kaefer M, Piva S, De Carvalho J, Da Silva D, Becker A, Coelho A, Duarte MM, Moresco RN.. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010;43:450–4.
- 16. Ates E, Set T, Karahan S, Bicer C, Erel O. Thiol/disulphide homeostasis, ischemia modified albumin, and ferroxidase as oxidative stress markers in women with obesity with insulin resistance. J Med Biochem 2019;38:445–51.
- 17. Tunc S, Atagun M, Neselioglu S, Bilgin Y, Basbug H, Erel O. Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders. Psychiat Clin Psych 2019;29:123–9.
- 18. Karasalan O, Hacımusalar Y, Amuk O, Bal C. Evaluation of ischemia modified albumin levels in major depression patients. J Surg Med 2019;3:557–60.
- 19. Beck A. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71.
- 20. Hisli N. A study on the validity of the Beck depression inventory. Turk Psychol J 1998;6:118–123.
- 21. Beck A, Epstein N, Brown G, Ster R. An Inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Phychol 1988;56:893–7.
- 22. Ulusoy M, Sahin N, Erkmen H. Turkish version of the Beck Anxiety Inventory: Psychometric properties. J Cogn Psychother 1998;12:163–72.
- 23. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006;97:1634–58.
- 24. Gingrich J. Oxidative stress is the new stress. Nat Med. 2005;11:1281–2.
- 25. Emhan A, Selek S, Bayazıt H, Karababa I, Katı M, Aksoy N. Evaluation of oxidative and antioxidative parameters in generalized anxiety disorder. Psychiatry Res 2015;230:806–10.
- 26. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Antioxidant enzyme and malondialdehyde levels in patients with social phobia. Psychiatry Res 2008;159:95–100.
- 27. Gautam M, Agrawal M, Gautam M, Sharma P, Gautam A, Gautam S. Role of antioxidants in generalised anxiety disorder and depression. Indian J Psychiatry 2012;54:244.
- 28. Bulut M, Selek S, Bez Y, Karababa I, Kaya M, Gunes M, Emhan A, Aksoy N, Sir A. Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder. J Affect Disord 2013;150:829–33.
- 29. Kabadayi Sahin E, Turan G, Neselioglu S, Can S, Atagun M. Thiol-disulphide homeostasis in patients with general anxiety disorder and panic disorder. Dusunen Adam J Psychiatry Neurol Sci 2019;32:289.
- 30. Herken H, Akyol O, Yilmaz H, Tutkun H, Savas H, Ozen M, Kalenderoglu A, Gulec M. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum Psychopharmacol Clin Exp 2006;21:53–9.
- 31. O’Donovan A, Hughes B, Slavich G, Lynch L, Cronin M, O’Farrelly C, Malone KM. Clinical anxiety, cortisol and interleukin-6: Evidence for specificity in emotion–biology relationships. Brain Behav Immun 2010;24:1074–7.
- 32. Fan J, Fan X, Li Y, Guo J, Xia D, Ding L, Zheng Q, Wang W, Xue F, Chen R, Liu S. Blunted inflammation mediated by NF-κB activation in hippocampus alleviates chronic normobaric hypoxia-induced anxiety-like behavior in rats. Brain Res Bull 2016;122:54–61.
- 33. Nakashima M, Ajiki K, Nakashima K, Takahashi M. Possible role of nitric oxide in anxiety following transient cerebral ischemia in mice. J Pharmacol Sci 2003;91:47–52.
- 34. Fernandes G, Frias A, Spiacci Jr A, Pinheiro L, TanusSantos, JE Zangrossi Jr H. Nitric oxide in the dorsal periaqueductal gray mediates the panic-like escape response evoked by exposure to hypoxia. Prog Neuro-Psychopharmacology Biol Psychiatry 2019;92:321–7.
- 35. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmächer T. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445–52.
- 36. Salim S, Asghar M, Taneja M, Hovatta I, Chugh G, Vollert C, Vu A. Potential contribution of oxidative stress and inflammation to anxiety and hypertension. Brain Res 2011;1404:63–71.
- 37. Asoglu M, Kilicaslan F, Beginoglu O, Fedai U, Akil O, Celik H, Buyukaslan H. Thiol/disulphide homeostasis as a new oxidative stress marker in untreated patients with generalized anxiety disorder. Anatol J Psychiatry 2018;19(2):143–9.
- 38. Arranz L, Guayerbas N, De la Fuente M. Impairment of several immune functions in anxious women. J Psychosom Res 2007;62:1–8.
| APA | Kabadayi Sahin E, Turan G, NEŞELİOĞLU S, Atagün M (2021). Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. , 153 - 159. 10.5505/kpd.2020.49404 |
| Chicago | Kabadayi Sahin Esra,Turan Gökçen,NEŞELİOĞLU Salim,Atagün Murat İlhan Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. (2021): 153 - 159. 10.5505/kpd.2020.49404 |
| MLA | Kabadayi Sahin Esra,Turan Gökçen,NEŞELİOĞLU Salim,Atagün Murat İlhan Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. , 2021, ss.153 - 159. 10.5505/kpd.2020.49404 |
| AMA | Kabadayi Sahin E,Turan G,NEŞELİOĞLU S,Atagün M Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. . 2021; 153 - 159. 10.5505/kpd.2020.49404 |
| Vancouver | Kabadayi Sahin E,Turan G,NEŞELİOĞLU S,Atagün M Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. . 2021; 153 - 159. 10.5505/kpd.2020.49404 |
| IEEE | Kabadayi Sahin E,Turan G,NEŞELİOĞLU S,Atagün M "Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder." , ss.153 - 159, 2021. 10.5505/kpd.2020.49404 |
| ISNAD | Kabadayi Sahin, Esra vd. "Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder". (2021), 153-159. https://doi.org/10.5505/kpd.2020.49404 |
| APA | Kabadayi Sahin E, Turan G, NEŞELİOĞLU S, Atagün M (2021). Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. Klinik Psikiyatri Dergisi, 24(2), 153 - 159. 10.5505/kpd.2020.49404 |
| Chicago | Kabadayi Sahin Esra,Turan Gökçen,NEŞELİOĞLU Salim,Atagün Murat İlhan Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. Klinik Psikiyatri Dergisi 24, no.2 (2021): 153 - 159. 10.5505/kpd.2020.49404 |
| MLA | Kabadayi Sahin Esra,Turan Gökçen,NEŞELİOĞLU Salim,Atagün Murat İlhan Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. Klinik Psikiyatri Dergisi, vol.24, no.2, 2021, ss.153 - 159. 10.5505/kpd.2020.49404 |
| AMA | Kabadayi Sahin E,Turan G,NEŞELİOĞLU S,Atagün M Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. Klinik Psikiyatri Dergisi. 2021; 24(2): 153 - 159. 10.5505/kpd.2020.49404 |
| Vancouver | Kabadayi Sahin E,Turan G,NEŞELİOĞLU S,Atagün M Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder. Klinik Psikiyatri Dergisi. 2021; 24(2): 153 - 159. 10.5505/kpd.2020.49404 |
| IEEE | Kabadayi Sahin E,Turan G,NEŞELİOĞLU S,Atagün M "Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder." Klinik Psikiyatri Dergisi, 24, ss.153 - 159, 2021. 10.5505/kpd.2020.49404 |
| ISNAD | Kabadayi Sahin, Esra vd. "Ischemia modified albumin: A potentialmarker for global metabolic risk in genera lized anxiety disorder and panic disorder". Klinik Psikiyatri Dergisi 24/2 (2021), 153-159. https://doi.org/10.5505/kpd.2020.49404 |
